What It Is
Mazdutide (research code IBI362) is a synthetic peptide drug candidate designed to activate two hormone receptors at once: the GLP-1 receptor and the glucagon receptor. It belongs to the same broad incretin-drug family as approved medicines like semaglutide and tirzepatide, but its specific dual-receptor combination is unique to its own clinical program.
Mazdutide is being developed mainly for obesity, overweight, and type 2 diabetes, with clinical trials concentrated in China, where its development is furthest along.[1] It is not a finished, approved medicine — it remains an investigational compound moving through clinical-trial phases.
How It Works
GLP-1 receptor activation reduces appetite, slows gastric emptying, and boosts glucose-dependent insulin release — the same mechanism behind approved GLP-1 drugs. Glucagon receptor activation is the unusual part: glucagon normally raises blood sugar, but it is also tied to energy expenditure and liver fat metabolism, so pairing it with GLP-1 is intended to add a metabolic boost beyond appetite suppression alone.
This dual-target design is a hypothesis about combined benefit, not a guarantee. Stimulating a glucose-raising pathway alongside a glucose-lowering one also creates distinct safety questions that single-target GLP-1 drugs do not have to manage.
What the Research Shows
Mazdutide has advanced through randomized, placebo-controlled Phase 2 and Phase 3 trials, mostly in Chinese adults, evaluating body-weight change in people with obesity or overweight and glycemic control in type 2 diabetes, including a head-to-head comparison against the approved GLP-1 drug dulaglutide.[9] Phase 3 obesity trials have reported weight loss at multiple weekly doses (in the 4 mg to 10 mg range) compared with placebo.[8]
This is genuine clinical-trial evidence, but it is still concentrated in one population, over a relatively short follow-up, and has not been replicated at the scale or geographic breadth of the evidence behind semaglutide or tirzepatide. Preclinical animal and mechanistic studies support the liver-fat and energy-expenditure rationale but do not establish outcomes in people.
Safety & Side Effects
- Gastrointestinal effects (nausea, vomiting, diarrhea, constipation, reduced appetite) are the most commonly reported issues and appear dose-related, consistent with the wider GLP-1 drug class
- Hypoglycemia risk is a specific watch point in diabetes trials, particularly when combined with insulin or sulfonylureas
- Class-wide GLP-1 concerns — pancreatitis, gallbladder disease, heart-rate changes — are relevant background context but have not been separately confirmed as mazdutide-specific findings
- Long-term cardiovascular outcomes, safety in pregnancy, and safety in broader, more diverse populations remain unestablished
Because mazdutide has no approved label, there is no regulator-reviewed adverse-event table to rely on; the safety picture comes only from trial reports to date.
Regulatory Status
Mazdutide is not FDA-approved and has no approved indication in the United States or European Union. It remains an investigational drug in sponsor-run clinical trials, with China's National Medical Products Administration furthest along in reviewing its development program.[1]
The FDA has separately warned about unapproved and compounded GLP-1-class products sold outside regulated drug channels.[6] A vial sold online as "mazdutide" is not the same as the drug substance used in registered clinical trials, and carries the same purity and quality uncertainty common to unregulated peptide sales.